Pharmacokinetics and Safety of Roledumab, a Fully Human Recombinant Monoclonal Anti-RhD Antibody, in RhD-negative Pregnant Woman Carrying an RhD-positive Foetus: a Phase IIb, Multicenter, Open-label Study
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Roledumab (Primary)
- Indications Haemolytic disease of newborn
- Focus Pharmacokinetics
- 01 Dec 2016 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 01 Dec 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.
- 01 Dec 2016 Status changed from recruiting to active, no longer recruiting.